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Background: This study investigated the influence of synthetic superparamagnetic iron oxide 
(SPIO) on dendritic cells and provides a possible method for labeling these cells.
Methods: SPIO nanoparticles were prepared, and their morphology and magnetic properties 
were characterized. The particles were endocytosed by dendritic cells generated from mouse 
bone marrow. Labeling efficiency and cellular uptake were analyzed by Prussian blue staining 
and quantitative spectrophotometric assay. Meanwhile, the surface molecules, cellular apoptosis, 
and functional properties of the SPIO-labeled dendritic cells were explored by flow cytometry 
and the mixed lymphocyte reaction assay.
Results: The synthetic nanoparticles possessed a spherical shape and good superparamagnetic 
behavior. The mean concentration of iron in immature and mature dendritic cells was 31.8 ± 0.7 µg 
and 35.6 ± 1.0 µg per 1 × 106 cells, respectively. After 12 hours of incubation with SPIO at a 
concentration of 25 µg/mL, nearly all cells were shown to contain iron. Interestingly, cellular 
apoptosis and surface expression of CD80, CD86, major histocompatibility II, and chemokine 
receptor 7 in mature dendritic cells were not affected to any significant extent by SPIO labeling. 
T cell activation was maintained at a low ratio of dendritic cells to T cells.
Conclusion: SPIO nanoparticles have good superparamagnetic behavior, highly biocompatible 
characteristics, and are suitable for use in further study of the migratory behavior and 
biodistribution of dendritic cells in vivo.
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Introduction
Due to their multifunctional properties, including a small size effect, superparamagnetism, 
and inherent biocompatibility, magnetic nanoparticles are being used increasingly for 
medical diagnosis and therapy, and especially for biomedical and biotechnology 
applications, including targeted drug delivery systems, contrast agents for magnetic 
resonance imaging, and hyperthermia for tumor therapy.1–3 In cell biology research, 
superparamagnetic iron oxide (SPIO) particles can be used for cell labeling, cell 
sorting, separation, and purification procedures.4–7 Although they are very promising 
for in vivo application in imaging and drug delivery, there has been concern about 
their biological safety, so their use has been restricted.
Dendritic cells are major antigen-presenting cells in the initiation and development 
of adaptive immune responses against bacteria, viruses, allergens, and tumor antigens. 
Essentially, dendritic cells induce potent immune responses via their ability to migrate 
from the periphery via afferent lymphatics to areas containing T cells in secondary 
lymphoid organs.8International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Immature dendritic cells residing in peripheral tissues 
monitor the microenvironment, and mature when starting 
to take up different antigens. During maturation, immature 
dendritic cells alter surface molecules, decreasing phagocytic 
ability, and strengthening their ability to migrate to lymph 
nodes, where they activate naive T cells via major histocom-
patibility complex (MHC) and costimulatory molecules.9–11
However, clinical studies of the ability of a dendritic 
cell vaccine to induce immunity against tumors did not 
demonstrate effective antitumor immunity.12,13 Because 
the responses of dendritic cell vaccine were not stable 
in clinical trials, monitoring of the injected cells may be 
important. Because of its ability to provide additional 
anatomical information and more detailed visualization, 
magnetic resonance imaging (MRI) may be an useful 
method for detecting labeled cells. The purpose of this study 
was to establish an efficient labeling method for dendritic 
cells in mouse bone marrow and to assess the influence of 
synthesized SPIO on dendritic cells for tracking them in vivo 
by MRI in the future.
Materials and methods
Materials
Ferric chloride (FeCl3 · 6H 2O), ferrous sulfate (FeSO4 · 7H 2O), 
and hydrochloric acid (30%) were purchased from 
Sinopharm Chemical Reagent Co Ltd, Shanghai, China. 
Tetramethylammonium hydroxide was from Shanghai 
Lingfeng Chemical Reagent Co Ltd, Shanghai, China. 
Other materials were RPMI 1640 medium, penicillin, 
and streptomycin (Gibco-Invitrogen, Grand Island, NY), 
fetal bovine serum (Gibco, Life Technologies, Breda, the 
Netherlands), recombinant murine granulocyte-macrophage 
colony-stimulating factor, recombinant murine interleukin-4, 
CD11c, B7-1 (CD80), B7-2(CD86), MHC II, and chemokine 
receptor 7 (eBioscience, San Diego, CA), tumor necrosis 
factor-α, interleukin-1β, and interleukin-6 (Peprotech, 
Rocky Hills, NJ), prostaglandin E2 (Sigma-Aldrich, St Louis, 
MO), a Prussian blue staining kit (Shanghai Yuanye   Bio-
Technology Co Ltd, China). Annexin V and propidium 
iodide (Biouniquer, Biostar, China), and the Cell Counting 
Kit-8 (Dojindo, Japan).
Preparation of sPIO
γ-Fe2O3 nanoparticles were prepared according to a method 
we have described previously.14 Briefly, 200 mL of aqueous 
tetramethylammonium hydroxide 1.5 M solution was added 
to a 500 mL aqueous solution containing FeCl3 0.1 M and 
FeSO4 0.05 M with vigorous stirring at room temperature for 
30 minutes. The resulting Fe3O4 nanoparticles were washed 
by magnetic separation and redispersed in water at pH 3.0 
and a concentration of 3 mg/mL, then oxidized into brown 
γ-Fe2O3 nanoparticles by aeration at 95°C. The γ-Fe2O3 nano-
particles obtained were dialyzed using an aqueous solution of 
hydrochloric acid at pH 3.0, and the final concentration was 
adjusted to 25 mg/mL for the cell labeling experiments.
The particle size and morphology of the γ-Fe2O3 
nanoparticles obtained was characterized by transmission 
electronic microscopy (JEOL JEM-2100). The magnetic 
properties were measured by a vibrating sample magnetometer 
(Lakeshore 7407). Photon correlation spectroscopy was used 
to determine the hydrodynamic size distribution using an 
N4 Plus submicron particle analyzer (Beckman Coulter, 
Indianapolis, IN), and surface charge measurements were 
performed using a Delsa 440SX zeta potential analyzer 
(Beckman Coulter).
Mice
Female BALB/c and C57BL/6 mice were purchased from the 
Animal Research Center of Yangzhou University, People’s 
Republic of China, and kept under pathogen-free conditions 
in the central animal facility at Nanjing University. In a 
typical experiment, bone marrow was isolated from the 
femurs of 8–10-week-old mice weighing from 20–22 g. 
All animal experiments were performed in accordance with 
protocols approved by the animal care and use committee of 
the Medical School, Nanjing University, China.
cell culture
Monocytes were isolated from mouse bone marrow. Marrow 
monocytes were flushed out from the femurs and tibias of the 
mice, cultured with RPMI 1640 medium supplemented with 
10% fetal bovine serum, 100 U/mL penicillin, 100 mg/mL 
streptomycin, 10 ng/mL recombinant murine granulocyte-
macrophage colony-stimulating factor, and 1 ng/mL 
recombinant murine interleukin-4.15 On days 2 and 4, 50% 
of the medium was removed and fresh media was added. 
The released immature, nonadherent dendritic cells were 
  collected on day 6. The cells were stimulated with 10 ng/mL 
tumor necrosis factor-α, 10 ng/mL interleukin-1β, 10 ng/mL 
interleukin-6, and 1 µg/mL prostaglandin E2 for 48 hours.16,17 
The mature dendritic cells were collected on day 8.
cell labeling and Prussian blue staining
Immature and mature dendritic cells were incubated with 
SPIO 25 µg/mL for 12 hours at 37°C in 5% CO2. Cells 
were washed three times in phosphate-buffered solution International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1781
superparamagnetic iron oxide and dendritic cells
and cytospins were prepared. Iron labeling efficiency was 
verified by Prussian blue staining. Labeled dendritic cells 
on cytospins were fixed with 4% paraformaldehyde for 
30   minutes at room temperature, washed, and incubated 
with 2%   potassium ferrocyanide in 2% hydrochloric acid for 
30 minutes, and washed again. Screenings were performed 
at high magnification (×400) using a light microscope 
(Olympus, CKX41-A32PH, Japan).
Flow cytometry
For phenotypic analysis, both labeled and unlabeled dendritic 
cells were harvested, washed thoroughly, individually stained 
with allophycocyanin-conjugated monoclonal antibodies 
specific for CD11c, fluorescein isothiocyanate-conjugated 
for MHC-II, phycoerythrin-conjugated for CD80, CD86, 
and chemokine receptor 7, according to the manufacturer’s 
instructions, and studied by flow cytometry (Calibur, Becton 
Dickinson, San Antonio, TX). Meanwhile, apoptosis rates 
were measured. Briefly, cells labeled or unlabeled with SPIO 
were collected, and stained with Annexin V and propidium 
iodide. After being washed, the apoptotic cells were studied 
by flow cytometry and analyzed using Cell Quest software.
cellular uptake of sPIO
The SPIO uptake by dendritic cells was assessed according 
to the method described by Ge et al.18 Briefly, immature 
and mature dendritic cells were collected, washed with 
phosphate-buffered saline, and resuspended in 30% HCl 
(v/v) at 60°C for two hours. Potassic persulfate 1.0 mg was 
then added to oxidize the ferrous ions in the above solution to 
ferric ions. Potassium thiocyanate 0.1 M 1.0 mL was added 
to form the iron-thiocyanate complex. A 150 µL quantity of 
the mixture was transferred to a flat-bottomed 96-well plate 
(Corning Costar, Cambridge, MA). The absorbance was 
measured at 480 nm using a microplate reader 10 minutes 
later (Bio-Tek Instruments Inc, Winooski, CT). A standard 
curve of an aqueous FeCl3 · 6H2O solution was treated in the 
same manner to quantify the amount of SPIO uptake in the 
cells. The iron content of the SPIO-labeled dendritic cells 
was expressed as the amount of Fe2O3.
Mixed lymphocyte reaction assay
Dendritic cells labeled with SPIO were collected and washed. 
Purified CD4+ T cells were obtained by positive magnetic 
bead separation (Miltenyi Biotec, Boston, MA) from the 
lymph nodes (axillary, inguinal, mesenteric) of normal 
BALB/c mice. Allogeneic T cells were incubated with 
dendritic cells or SPIO-labeled dendritic cells at ratios of 5:1, 
10:1, 50:1, and 100:1 in flat-bottomed 96-well plates. After 
incubation for three days, cell activation and proliferation was 
evaluated using a Cell Counting Kit-8, and the absorbances 
were read at 450 nm using the microplate reader according 
to the manufacturer’s instructions.
statistical analysis
Data were analyzed using the Statistical Package for Social 
Science (version 13.0, SPSS Inc, Chicago, IL). Results were 
expressed as means ± standard deviation, and differences 
between control and test groups were assessed by one-way 
analysis of variance and two-tailed Student’s t-test. The level 
of statistical significance was set at P , 0.05.
Results
characterization of sPIO
Under transmission electron microscopy, γ-Fe2O3 nanopar-
ticles were measured at an average diameter around 8.7 nm, 
and were seen as nearly spherical shapes (Figure 1A). 
A vibrating sample magnetometer demonstrated that the 
γ-Fe2O3 nanoparticles obtained possessed superparamagnetic 
behavior, with saturation magnetization of 60.4 emu/g 
(Figure 1B). The average hydrodynamic size of the γ-Fe2O3 
nanoparticles in water was 92 nm, and the zeta potential had 
a positive surface charge of 20.9 mV .
SPIO labeling efficiency and cell 
phenotypes
Prussian blue staining was performed to evaluate SPIO 
labeling efficiency. After 12 hours of incubation with SPIO 
at a concentration of 25 µg/mL, nearly all cells were shown 
to contain iron (Figure 2). Before study of the phenotypic 
changes in labeled dendritic cells, the ratio of dendritic 
cells in the induced marrow monocytes was analyzed. The 
results indicated that 80% of the cells were CD11c+, which is 
regarded as a major marker for dendritic cells (Figure 3).
To determine whether dendritic cell surfaces would be 
influenced by SPIO labeling, an immunostaining assay was 
performed with a panel of antibodies against the costimu-
latory molecules CD80, CD86, MHC-II, and chemokine 
receptor 7, followed by flow cytometry analysis. After 
being stimulated by tumor necrosis factor-α, interleukin-1β, 
interleukin-6, and prostaglandin E2, expression of CD80, 
CD86, MHC-II, and chemokine receptor 7 was significantly 
increased in mature dendritic cells compared with immature 
dendritic cells. Expression of these four markers in mature 
dendritic cells and mature SPIO-labeled dendritic cells was 
similar, with no statistically significant difference between the International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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groups (P . 0.05). In contrast, compared with unlabeled cells, 
expression of CD80, CD86, and MHC-II on SPIO-labeled 
immature dendritic cells was upregulated, while chemokine 
receptor 7 remained at almost the same level (Figure 4). 
cell apoptosis
To test whether dendritic cells labeled with SPIO nano-
particles could have any influence on cell apoptosis, both 
mature dendritic cells and mature SPIO-labeled dendritic 
cells were analyzed by flow cytometry using Annexin 
V-propidium iodide methods at different time points (0, 6, 
12, 24, and 36 hours). The results indicate no significant 
difference in cell apoptosis between mature dendritic cells 
and mature SPIO-labeled dendritic cells (Figure 5).
cellular uptake of sPIO
SPIO particles internalized by dendritic cells were examined 
using a quantitative spectrophotometric method. There was a 
linear correlation (r2 . 0.99) between absorbance and concen-
tration of nanoparticles in culture medium. On average, the 
mean concentration of iron in immature SPIO-labeled den-
dritic cells and mature SPIO dendritic cells was 31.8 ± 0.7 µg 
and 35.6 ± 1.0 µg per 1 × 106 cells, respectively (Figure 6).
Mixed lymphocyte reaction assay
The mixed lymphocyte reaction assay used to observe the 
functional properties of SPIO-labeled dendritic cells used 
ratios of dendritic cells to T cells of 1:5, 1:10, 1:50, and 
1:100, respectively. Activation and proliferation of T cells 
was notably decreased as the ratios decreased from 1:5 to 
1:100. Both mature SPIO-labeled and unlabeled dendritic 
cells showed a significant increase in T cell activation and 
proliferation when the ratio of dendritic cells to T cells was 
1:5. Similar results were observed for immature dendritic 
cells and immature SPIO-labeled dendritic cells, but the 
absorbance of mature SPIO-labeled dendritic cells was lower 
than that of mature dendritic cells (P , 0.05). There was no 
significant difference detected at other ratios (Figure 7).
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Figure 3 cD11c+ cells were examined by flow cytometry after being stained with 
allophycocyanin-conjugated monoclonal antibodies.
Abbreviation: APc, allophycocyanin.
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Figure 1 characteristics of γ-Fe2O3 nanoparticles. (A) Transmission electron microscopic image of the obtained γ-Fe2O3 nanoparticles and (B) hysteresis loop of the 
obtained γ-Fe2O3 nanoparticles at room temperature.
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Figure 2 Morphology of dendritic cells labeled with 25 µg/mL superparamagnetic 
iron  oxide  particles  after  12  hours  incubation  (Prussian  blue  staining,  ×400). 
(A) unlabeled dendritic cells, (B) dendritic cells labeled with superparamagnetic iron 
oxide, and (C) labeled dendritic cells with Prussian blue staining.
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Figure 4 Phenotypic changes of dendritic cells after labeling with superparamagnetic iron oxide particles.
Abbreviations: iDcs, immature dendritic cells; mDcs, mature dendritic cells; sPIO, superparamagnetic iron oxide.
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12, 24, and 36 hours). (A) Cell apoptosis by flow cytometry and (B) cell death curve.
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Discussion
The basic criteria for the use of  SPIO in bioscience are safety 
and biocompatibility, which are determined by size and 
superficial characteristics. Superparamagnetic Fe3O4 nano-
particles have demonstrated good biocompatibility and safety 
when used as drug carriers and targeted tumor therapy.19,20 
γ-Fe2O3 nanoparticles with a positive surface charge were 
synthesized by oxidation and acidification from Fe3O4 and 
had a good superparamagnetic behavior. The precursors 
were prepared according to a modified Massart method and 
reduction coprecipitation without argon protection.21,22 SPIO 
preparation was simple and feasible, and the characteristics 
of synthetic SPIO were proved to be suitable for biological 
application (Figure 1).
Because the immune response of dendritic cell vaccines 
against solid tumors has often been shown to be weak or 
localized, there has been concern about the need to track 
migration of dendritic cells accurately in vivo. In this study, 
a novel approach to forming SPIO-labeled dendritic cells 
was introduced, and the influence of SPIO on dendritic cells 
was investigated. SPIO is an attractive contrast agent for cell 
migration. It is a biodegradable and feasible agent for study 
of living cells by MRI in vitro and in vivo.14,23 Due to the 
phagocytic properties and negative membrane potential of 
dendritic cells, SPIO-labeled nanoparticles could be easily 
delivered to the cells.24 In our study, SPIO was internalized 
into dendritic cells, and this was confirmed by Prussian blue 
staining (Figure 2).
Before evaluating the influence of SPIO-labeled dendritic 
cells, the dendritic cells were first identified. CD11c is widely 
regarded as a major marker for dendritic cells. In this study, 
flow cytometry indicated that 80% of bone marrow mono-
cytes were CD11c+, showing this to be a reliable method for 
providing sufficient cells for further studies (Figure 3).
Phenotype and maturation of dendritic cells are critical 
factors which may be changed by SPIO labeling. In our 
study, after immature dendritic cells were labeled by SPIO, 
expression of CD80, CD86, and MHC II was found to be 
upregulated, while chemokine receptor 7 levels remained 
unchanged. We hypothesize that SPIO was engulfed as 
antigens by immature dendritic cells, which induced early 
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Figure 7 Mixed lymphocyte reaction of dendritic cells and superparamagnetic iron 
oxide impregnated dendritic cells with allogeneic T cells. Dendritic cells derived 
from bone marrow and labeled with sPIO (25 µg/mL, 12 hours of incubation) were 
cocultured with allogenic T cells for 3 days at ratios of 1:5, 1:10, 1:50, 1:100, and 
proliferation of T cells was measured by the cell counting Kit-8 method (450 nm).
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maturation of these dendritic cells. Although MHC II was 
upregulated, there were no actual antigen formation via 
MHC II which could explain the unaltered expression of 
chemokine receptor 7. After stimulation by inflammatory 
cytokines, ie, tumor necrosis factor-α, interleukin-1β, 
interleukin-6, and prostaglandin E2, the expression of these 
four markers was increased significantly in both labeled and 
unlabeled mature dendritic cells. These findings suggested 
that SPIO had little influence on the phenotypes of mature 
dendritic cells (Figure 4). Moreover, there was no significant 
change in apoptosis after SPIO labeling (Figure 5).
Furthermore, the concentration of intracellular iron in 
SPIO-labeled dendritic cells was measured. The optimal 
concentration and coculture time of SPIO for dendritic 
cell-labeling were 25 µg/mL and 12 hours, respectively, 
as shown in our previous study (data not shown). Cells 
containing iron were found to carry an average amount of 
31.8 ± 0.7 µg per 1 × 106 cells in immature dendritic cells 
and 35.6 ± 1.0 µg per 1 × 106 cells in mature dendritic cells 
(Figure 6). Verdijk et al25 have shown that an average of 
30 µg iron per 1 × 106 cells will not hinder cell viability, 
with the   concentration of SPIO in their study set as 200 µg 
  ferrum oxide/mL and a coculture time of 4 days. In contrast, 
this type of synthetic SPIO was shown to be more easily 
inserted, independent of concentration or coculture time, 
than   suggested by previous reports.25,26
To confirm whether SPIO labeling could affect function 
and apoptosis of dendritic cells, the capacities of antigen-
processing, presenting, and naive allogeneic T cells 
stimulated by dendritic cells were tested by a mixed leukocyte 
reaction assay. The results showed that dendritic cells could 
maintain T cell activation and proliferation after being labeled 
by SPIO, except if the ratio of dendritic cells to T cells was 
1:5, when the stimulating ability of mature dendritic cells 
was partly limited by SPIO. A similar phenomenon was not 
found for the other experimental groups (Figure 7). Because 
the proportion of dendritic cells in the peripheral tissues was 
very low, the number of dendritic cells migrating from the 
periphery to the secondary lymphoid organs was estimated 
to be less than 10%,8,28 and the possibility of the ratio being 
restricted to 1:5 was almost impossible. Similar results have 
been obtained using other types of SPIO.29
Conclusion
From the data presented, SPIO has a negligible influence on 
dendritic cell function, especially mature dendritic cells. This 
study describes a novel approach for MRI investigation of 
dendritic cell migration. Hopefully, our work will serve as a 
useful method for evaluating activation of the immune response 
against tumor tissue by dendritic cell vaccines in the future.
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